Real-World Observational Study of Somatostatin Analogs and Rescue Medication Usage for Neuroendocrine Tumors in Canada
Neuroendocrinology · 17.03.2026 · 116 (4) · 219-228
DOI: 10.1159/000551525 ↗Kurz gefasst
Beobachtungsstudie in der Zeitschrift Neuroendocrinology, online erschienen am 17.03.2026. Verfasst von Daniel Rayson und 4 weiteren Autor:innen. Beteiligte Einrichtung: Division of Medical Oncology, Dalhousie University, Halifax, Nova Scotia, Canada, daniel.rayson@nshealth.ca. Hauptthemen laut MEDLINE: Neuroendocrine Tumors, Somatostatin, Octreotide, Peptides, Cyclic. Die Arbeit nennt 30 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0).
Abstract (Originalsprache)
Introduction
Neuroendocrine tumors (NETs) are uncommon malignancies with increasing incidence in Canada. Long-acting somatostatin analogs (SSA) such as Lanreotide Autogel® (LAN-ATG) and Octreotide Long-Acting Release (OCT-LAR) are first-line treatments for well-differentiated gastroenteropancreatic neuroendocrine tumors either with or without carcinoid syndrome. Despite their efficacy, many patients require short-acting SSA for breakthrough symptoms. We investigated the impact of switching between long-acting SSAs on the usage of breakthrough medications and the incidence of above maximum recommended dose (AMRD) prescriptions.
Methods
This population-based study used claims data from the IQVIA Canadian Private Drug Plan (PDP) that includes data from all Canadian provinces and public drug programs from Ontario and Québec. We identified NET patients who switched SSAs between September 2015 and December 2021. We analyzed breakthrough medication usage and AMRD prescriptions before and after the switch.
Results
Among 170 patients who switched SSAs, there was a 59.1% overall reduction in breakthrough medication claims post-switch. Patients switching from OCT-LAR to LAN-ATG experienced a 66.5% reduction, while those switching from LAN-ATG to OCT-LAR saw a 21.9% decrease. Pre-switch, significantly more patients on OCT-LAR exceeded the AMRD threshold compared to those on LAN-ATG (43.8% vs. 18.2%, p value = 0.008).
Conclusion
Switching between long-acting SSAs can reduce the need for breakthrough medications and lower the incidence of AMRD prescriptions, with a more pronounced effect observed when switching from OCT-LAR to LAN-ATG. These findings have potential implications for improving quality of life and reducing treatment costs for NET patients, which should be evaluated in a formal health economic analysis.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Division of Medical Oncology, Dalhousie University, Halifax, Nova Scotia, Canada, daniel.rayson@nshealth.ca.
- Ipsen Biopharmaceuticals Canada, Mississauga, Ontario, Canada.
- IQVIA, Toronto, Ontario, Canada.
- Department of Oncology, University of Calgary, Calgary, Alberta, Canada.
- Division of Medical Oncology, BC Cancer, Vancouver, British Columbia, Canada.
Zitieren
APA
Rayson, D., Troesch, M., LaForty, C., Cheung, W., & Loree, J. (2026). Real-World Observational Study of Somatostatin Analogs and Rescue Medication Usage for Neuroendocrine Tumors in Canada. Neuroendocrinology, 116(4), 219-228. https://doi.org/10.1159/000551525
Vancouver
Rayson D, Troesch M, LaForty C, Cheung W, Loree J. Real-World Observational Study of Somatostatin Analogs and Rescue Medication Usage for Neuroendocrine Tumors in Canada. Neuroendocrinology. 2026;116(4):219-228. doi:10.1159/000551525
BibTeX
@article{Rayson2026,
author = {Rayson, Daniel and Troesch, Myriam and LaForty, Callahan and Cheung, Winson and Loree, Jonathan},
title = {Real-World Observational Study of Somatostatin Analogs and Rescue Medication Usage for Neuroendocrine Tumors in Canada},
journal = {Neuroendocrinology},
year = {2026},
volume = {116},
number = {4},
pages = {219--228},
doi = {10.1159/000551525}
}
EUVIMED